07:00 , Aug 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Scars/wrinkles ADAM metallopeptidase domain 12 (ADAM12) Mouse studies suggest inhibiting ADAM12 could help prevent tissue fibrosis and...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Clinical News

Bladder Cancer Assay diagnostic data

A trial in urine samples from patients with bladder cancer and healthy controls showed that Predictive's CertNDx Bladder Cancer Assay using MMP2, FGFR3, TWIST1 and NID2 biomarkers had 94% specificity and a 99.5% negative predictive...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Clinical News

Bladder cancer assay: Pilot trial data

A pilot study of urine samples from 181 patients with bladder cancer showed that the sensitivity and negative predictive value of Predictive's bladder cancer assay using MMP9, MMP2, ADAM12 and FGFR3 biomarkers increased to 96%...
08:00 , Jan 21, 2008 |  BioCentury  |  Emerging Company Profile

Predictive Bio: Putting cancer in silos

A non-invasive diagnostic that could determine the presence or absence of cancer would significantly reduce the number of patients who unnecessarily go through colonoscopies, cystoscopies and biopsies only to discover they are disease free. Predictive...
07:00 , Jun 20, 2005 |  BC Week In Review  |  Company News

PerkinElmer, University of Copenhagen deal

The university granted PKI a license to develop assay kits for ADAM12, which is a marker for fetal chromosomal abnormalities, intrauterine growth retardation and preeclampsia. The license is exclusive in North America and co-exclusive...
08:00 , Dec 24, 2001 |  BC Week In Review  |  Company News

Osaka University other research news

Scientists reported in Nature Medicine that in a model of chronic heart failure, mice treated with KB-R7785 showed significantly reduced cardiac hypertrophy, evaluated as a ratio of heart weight to body weight and by ventricular...